Preclinical Data

In a canine model, Chronic delivery of BackBeat® CNT significantly reduced 24-hour systolic and diastolic blood pressures

The goal of the preclinical studies was to demonstrate the feasibility of the use of BackBeat® CNT in a canine model with surgically induced hypertension and provide a rationale for use to chronically lower blood pressure in patients with hypertension.

BackBeat® CNT was delivered safely and effectively via pacing algorithms in a prototype device in the canine model. Chronic delivery of BackBeat® CNT significantly reduced 24-hour real-time systolic and diastolic blood pressure by 32.5 mmHg and 10.8 mmHg compared to a control that had no change. The reduction occurred immediately upon activation of therapy and was maintained for the period that the therapy was active. Upon the discontinuation of therapy, blood pressure did not immediately return to baseline level but rather gradually increased, suggesting that the therapy may have an impact on the setpoint of the blood pressure control mechanism.

BackBeat® CNT demonstrated a marked decrease in BP during treatment in preclinical studies. Each point represents 24-hour average. Slow return to baseline BP indicates modulation of autonomic nervous system response.

Have any questions?
Contact us at 917.254.4900 or info@orchestrabiomed.com